Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of setmelanotide for obesity due to genetic leptin-melanocortin pathway defects
2017-005006-35Phase 3Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Jan 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of setmelanotide in obesity, sponsored by Rhythm Pharmaceuticals. Primary endpoint: Primary safety and tolerability. Started Jan 2018; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on 2017-005006-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005006-35.